ADIAL PHARMACEUTICALS, INC. ADIL
are a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction
and related disorders. Our investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol
use disorder ("AUD"). AD04 was investigated in a Phase 3 clinical trial, designated the ONWARD trial, for the potential treatment
of AUD in subjects with certain target genotypes, which were identified using our companion diagnostic genetic test. Based on our analysis
Last close
3.92
2026-10-23
Market cap
$10.3M
2026-06-30 share count
52-week range
1.31 - 9.53
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-11.93
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $2.6M | $3.2M | $1.3M | $2.0M | $8.4M | $5.9M | $4.0M | $368.5K | $182.1K | — |
| SG&A | $5.2M | $5.1M | $5.6M | $8.9M | $9.3M | $5.1M | $4.3M | $6.6M | $813.2K | — |
| Total operating expenses | $7.8M | $8.3M | $6.9M | $10.9M | $19.3M | $10.9M | $8.2M | $7.0M | $995.3K | — |
| Operating income | -$7.8M | -$8.3M | -$6.9M | -$10.9M | -$19.3M | -$10.9M | -$8.2M | -$7.0M | -$995.3K | — |
| Pre-tax income | -$8.0M | -$13.2M | -$7.0M | -$10.8M | -$19.5M | -$10.9M | -$8.6M | -$11.6M | -$1.1M | — |
| Income tax | — | — | — | $502 | $94.1K | — | — | — | — | — |
| Net income | -$7.98T | -$13.20T | -$5.12T | -$12.7M | -$19.4M | -$10.9M | -$8.6M | -$11.6M | -$1.1M | — |
| EPS, basic | -11.93 | -68.01 | -3.60 | -12.71 | -1.04 | — | — | — | — | — |
| EPS, diluted | -11.93 | -68.01 | -3.60 | -12.71 | -1.04 | -0.87 | -0.87 | -2.44 | -0.35 | — |
| Shares, diluted (wtd. avg.) | 668,630 | 194,059 | 1.4M | 1.0M | 18.6M | — | — | 243,182 | 174,282 | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $5.9M | $3.8M | $2.8M | $4.0M | $6.1M | $4.4M | $6.8M | $3.9M | $18.2K | $88.0K |
| Total current assets | $6.2M | $4.1M | $3.2M | $4.8M | $6.5M | $5.1M | $7.7M | $4.7M | $27.2K | — |
| Property, plant and equipment | — | — | — | $50.4K | $58.1K | — | — | — | — | — |
| Goodwill | — | — | — | $249.0K | $249.0K | — | — | — | — | — |
| Other intangibles | $2.8K | $3.3K | $3.9K | $4.5K | $5.0K | $5.6K | $6.2K | $6.7K | $7.3K | — |
| Total assets | $6.7M | $5.0M | $4.7M | $5.7M | $7.5M | $5.5M | $7.7M | $4.7M | $34.5K | — |
| Accounts payable | $655.2K | $250.1K | $103.3K | $276.4K | $286.2K | $648.7K | $190.2K | $99.7K | $342.1K | — |
| Total current liabilities | $1.4M | $975.9K | $653.1K | $1.8M | $2.7M | $1.5M | $539.1K | $258.0K | $1.0M | — |
| Total liabilities | $1.4M | $975.9K | $653.1K | $2.5M | $4.0M | $1.5M | — | — | — | — |
| Retained earnings | -$90.0M | -$82.0M | -$68.8M | -$63.7M | -$50.9M | -$31.5M | -$20.6M | -$12.0M | -$404.0K | — |
| Total equity | $5.3M | $4.1M | $4.1M | $3.3M | $3.5M | $4.0M | $7.1M | $4.4M | -$997.6K | -$103.5K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.5M | -$6.9M | -$6.8M | -$11.2M | -$11.9M | -$7.6M | -$6.3M | -$2.5M | -$494.9K | — |
| Stock-based compensation | $676.2K | $796.8K | $1.7M | $3.4M | $4.2M | $2.0M | $1.6M | $5.4M | $205.4K | — |
| Capital expenditure | — | — | — | — | $64.6K | — | — | — | — | — |
| Investing cash flow | $150.0K | — | $1.5M | — | -$34.0K | -$350.0K | — | — | $35.1K | — |
| Financing cash flow | $8.5M | $7.8M | $4.1M | $9.1M | $13.6M | $5.6M | $9.2M | $6.3M | $390.0K | — |
| Buybacks | — | — | $1.7K | — | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-093019.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | — | -$1.1M | -$11.6M | -$8.6M | -$10.9M | -$19.4M | -$12.7M | -$5.12T | -$13.20T | -$7.98T |
Recent filings and events
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Acquisition or disposal completed A purchase or sale of a significant business or asset has closed. Item 2.01
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
- Unregistered share sale Item 3.02
- Officer or director change Item 5.02
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |